ABC Transporters: Unvalidated Therapeutic Targets in Cancer and the CNS

Anti-Cancer Agents in Medicinal Chemistry

Volumn 10, Issue 8, 2010, Pages 625-633

  Robey, Robert W ^a   Massey, Paul R ^a   Amiri Kordestani, Laleh ^a   Bates, Susan E ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

ABC transporters; Drug resistance; P glycoprotein

Indexed keywords

ABC TRANSPORTER; BIRICODAR; CBT 1; CYCLOSPORIN A; DASATINIB; DOFEQUIDAR; DOXORUBICIN; ELACRIDAR; ERLOTINIB; FLAVOPIRIDOL; GEFITINIB; GLYCOPROTEIN P; IMATINIB; LAPATINIB; OLAPARIB; SORAFENIB; TARIQUIDAR; TOPOTECAN; UNCLASSIFIED DRUG; VALSPODAR; VERAPAMIL; ZOSUQUIDAR;

ACUTE GRANULOCYTIC LEUKEMIA; BREAST CANCER; CANCER RESISTANCE; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; DOSE RESPONSE; DRUG ACCUMULATION; DRUG EFFICACY; DRUG TARGETING; DRUG TRANSPORT; DRUG UPTAKE; HUMAN; IN VITRO STUDY; LEUKEMIA; LUNG CANCER; MYELOMA; NONHUMAN; OUTCOME ASSESSMENT; OVARY CANCER; PROTEIN FUNCTION; REVIEW;

EID: 79551647898     PISSN: 18715206     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152010794473957     Document Type: Review

References (70)

1. Gottesman, M.M.; Fojo, T.; Bates, S.E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer, 2002, 2(1), 48-58.
2. Cascorbi, I. Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. Pharmacol. Ther., 2006, 112(2), 457-73.
3. Deeken, J.F.; Loscher, W. The blood-brain barrier and cancer: transporters, treatment, and Trojan horses. Clin. Cancer Res., 2007, 13(6), 1663-1674.
4. Robey, R.W.; Polgar, O.; Deeken, J.; To, K.W.; Bates, S.E. ABCG2: determining its relevance in clinical drug resistance. Cancer Metastasis Rev., 2007, 26(1), 39-57.
5. Leonard, G.D.; Fojo, T.; Bates, S.E. The role of ABC transporters in clinical practice. Oncologist, 2003, 8(5), 411-424.
6. van der Kolk, D.M.; de Vries, E.G.; Müller, M.; Vellenga, E. The role of drug efflux pumps in acute myeloid leukemia. Leuk Lymphoma, 2002, 43(4), 685-701.
7. Sonneveld, P. Multidrug resistance in haematological malignancies. J. Intern. Med., 2000, 247(5), 521-534.
8. Steinbach, D.; Legrand, O. ABC transporters and drug resistance in leukemia: was P-gp nothing but the first head of the Hydra? Leukemia, 2007, 21(6), 1172-1176.
9. Wilson, C.S.; Davidson, G.S.; Martin, S.B.; Andries, E.; Potter, J.; Harvey, R.; Ar, K.; Xu, Y.; Kopecky, K.J.; Ankerst, D.P.; Gundacker, H.; Slovak, M.L.; Mosquera-Caro, M.; Chen, I.M.; Stirewalt, D.L.; Murphy, M.; Schultz, F.A.; Kang, H.; Wang, X.; Radich, J.P.; Appelbaum, F.R.; Atlas, S.R.; Godwin, J.; Willman, C.L. Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome prediction. Blood, 2006, 108(2), 685-696.
10. Leonessa, F.; Clarke, R. ATP binding cassette transporters and drug resistance in breast cancer. Endocr. Relat. Cancer, 2003, 10(1), 43-73.
11. Takara, K.; Sakaeda, T.; Okumura, K. An update on overcoming MDR1-mediated multidrug resistance in cancer chemotherapy. Curr. Pharm. Des., 2006, 12(3), 273-286.
12. Ozols, R.F.; Cunnion, R.E.; Klecker, R.W.; Hamilton, T.C.; Ostchega, Y.; Parrillo, J.E.; Young, R.C. Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients. J. Clin. Oncol., 1987, 5, 641-647.
13. Seiden, M.V.; Swenerton, K.D.; Matulonis, U.; Campos, S.; Rose, P.; Batist, G.; Ette, E.; Garg, V.; Fuller, A.; Harding, M.W.; Charpentier, D. A phase II study of the MDR inhibitor biricodar (INCEL, VX-710) and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy. Gynecol. Oncol., 2002, 86(3), 302-310.
14. Fracasso, P.M.; Brady, M.F.; Moore, D.H.; Walker, J.L.; Rose, P.G.; Letvak, L.; Grogan, T.M.; McGuire, W.P. Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovarian carcinoma: a gynecologic oncology group study. J. Clin. Oncol., 2001, 19(12), 2975-2982.
15. Chico, I.; Kang, M.H.; Bergan, R.; Abraham, J.; Bakke, S.; Meadows, B.; Rutt, A.; Robey, R.; Choyke, P.; Merino, M.; Goldspiel, B.; Smith, T.; Steinberg, S.; Figg, W.D.; Fojo, T.; Bates, S. Phase I study of infusional paclitaxel in combination with the Pglycoprotein antagonist PSC 833. J. Clin. Oncol., 2001, 19(3), 832-842.
16. Fox, E.; Bates, S.E. Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor. Expert Rev. Anticancer. Ther., 2007, 7(4), 447-459.
17. Cripe, L.D.; Uno, H.; Paietta, E.M.; Litzow, M.R.; Ketterling, R.P.; Bennett, J.M.; Rowe, J.M.; Lazarus, H.M.; Luger, S.; Tallman, M.S. Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999. Blood, 2010, 116(20), 4077-4085.
18. Patel, K.J.; Tannock, I.F. The influence of P-glycoprotein expression and its inhibitors on the distribution of doxorubicin in breast tumors. BMC Cancer, 2009, 9, 356.
19. Lankelma, J.; Dekker, H.; Luque, F.R.; Luykx, S.; Hoekman, K.; van der Valk, P.; van Diest, P.J.; Pinedo, H.M. Doxorubicin gradients in human breast cancer. Clin. Cancer Res., 1999, 5(7), 1703-1707.
20. Rottenberg, S.; Jaspers, J.E.; Kersbergen, A.; van der Burg, E.; Nygren, A.O.; Zander, S.A.; Derksen, P.W.; de Bruin, M.; Zevenhoven, J.; Lau, A.; Boulter, R.; Cranston, A.; O'Connor, M.J.; Martin, N.M.; Borst, P.; Jonkers, J. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc. Natl. Acad. Sci. USA, 2008, 105(44), 17079-17084.
21. Pajic, M.; Iyer, J.K.; Kersbergen, A.; van der Burg, E.; Nygren, A.O.; Jonkers, J.; Borst, P.; Rottenberg, S. Moderate increase in Mdr1a/1b expression causes in vivo resistance to doxorubicin in a mouse model for hereditary breast cancer. Cancer Res., 2009, 69(16), 6396-6404.
22. Zander, S.A.; Kersbergen, A.; van der Burg, E.; de Water, N.; van Tellingen, O.; Gunnarsdottir, S.; Jaspers, J.E.; Pajic, M.; Nygren, A.O.; Jonkers, J.; Borst, P.; Rottenberg, S. Sensitivity and acquired resistance of BRCA1;p53-deficient mouse mammary tumors to the topoisomerase I inhibitor topotecan. Cancer Res., 2010, 70(4), 1700-1710.
23. Rottenberg, S.; Nygren, A.O.; Pajic, M.; van Leeuwen, F.W.; van der Heijden, I.; van de Wetering, K.; Liu, X.; de Visser, K.E.; Gilhuijs, K.G.; van Tellingen, O.; Schouten, J.P.; Jonkers, J.; Borst, P. Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer. Proc. Natl. Acad. Sci. USA, 2007, 104(29), 12117-12122.
24. Boonstra, R.; Timmer-Bosscha, H.; van Echten-Arends, J.; van der Kolk, D.M.; van den Berg, A.; de Jong, B.; Tew, K.D.; Poppema, S.; de Vries, E.G. Mitoxantrone resistance in a small cell lung cancer cell line is associated with ABCA2 upregulation. Br. J. Cancer, 2004, 90(12), 2411-2417.
25. Ritter, C.A.; Jedlitschky, G.; Meyer zu Schwabedissen, H.; Grube, M.; Köck, K.; Kroemer, H.K. Cellular export of drugs and signaling molecules by the ATP-binding cassette transporters MRP4 (ABCC4) and MRP5 (ABCC5). Drug Metab. Rev., 2005, 37(1), 253-278.
26. Franke, R.M.; Gardner, E.R.; Sparreboom, A. Pharmacogenetics of drug transporters. Curr. Pharm. Des., 2010, 16(2), 220-230.
27. Gerlinger, M.; Swanton, C. How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine. Br. J. Cancer, 2010, 103(8), 1139-1143.
28. Ceriani, L.; Giovanella, L.; Bandera, M.; Beghe, B.; Ortelli, M.; Roncari, G. Semi-quantitative assessment of 99Tcm-sestamibi uptake in lung cancer: relationship with clinical response to chemotherapy. Nucl. Med. Commun., 1997, 18(11), 1087-1097.
29. Nishiyama, Y.; Yamamoto, Y.; Satoh, K.; Ohkawa, M.; Kameyama, K.; Hayashi, E.; Fujita, J.; Tanabe, M. Comparative study of Tc-99m MIBI and TI-201 SPECT in predicting chemotherapeutic response in non-small-cell lung cancer. Clin. Nucl. Med., 2000, 25(5), 364-369.
30. Yüksel, M.; Cermik, T.; Doǧanay, L.; Karlikaya, C.; Cakir, E.; Salan, A.; Berkarda, S. 99mTc-MIBI SPET in non-small cell lung cancer in relationship with Pgp and prognosis. Eur. J. Nucl. Med. Mol. Imaging, 2002, 29(7), 876-881.
31. Komori, T.; Narabayashi, I.; Matsui, R.; Sueyoshi, K.; Aratani, T.; Utsunomiya, K., Ann. Nucl. Med., 2000, 14(6), 415-420.
32. Fuster, D.; Vinolas, N.; Mallafre, C.; Pavia, J.; Martin, F.; Pons, F. Tetrofosmin as predictors of tumour response. Q. J. Nucl.Med., 2003, 47(1), 58-62.
33. Shih, C.; Shiau, Y.; Wang, J.; Ho, S.; Kao, A. Using technetium-99m tetrofosmin chest imaging to predict taxol-based chemotherapy response in non-small cell lung cancer but not related to lung resistance protein expression. Lung, 2003, 181(2), 103-111.
34. Mohan, H.K.; Miles, K.A. Cost-effectiveness of 99mTc-sestamibi in predicting response to chemotherapy in patients with lung cancer: systematic review and meta-analysis. J. Nucl. Med., 2009, 50(3), 376-381.
35. Gomes, C.M.; Abrunhosa, A.J.; Pauwels, E.K.; Botelho, M.F. P-glycoprotein versus MRP1 on transport kinetics of cationic lipophilic substrates: a comparative study using [99mTc]sestamibi and [99mTc]tetrofosmin. Cancer Biother. Radiopharm., 2009, 24(2), 215-227.
36. Kelly, R.J.; Draper, D.; Chen, C.C.; Robey, R.W.; Figg, W.D.; Piekarz, R.L.; Chen, X.; Gardner, E.R.; Balis, F.M.; Venkatesan, A.M.; Steinberg, S.M.; Fojo, A.T.; Bates, S.E. A Pharmacodynamic study of docetaxel in combination with the pglycoprotein antagonist, tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer. Clin. Cancer Res., 2010.
37. Agrawal, M.; Abraham, J.; Balis, F.M.; Edgerly, M.; Stein, W.D.; Bates, S.; Fojo, T.; Chen, C.C. Increased 99mTc-sestamibi accumulation in normal liver and drug-resistant tumors after the administration of the glycoprotein inhibitor, XR9576. Clin. Cancer Res., 2003, 9(2), 650-656.
38. Memon, A.A.; Jakobsen, S.; Dagnaes-Hansen, F.; Sorensen, B.S.; Keiding, S.; Nexo, E. Positron emission tomography (PET) imaging with [11C]-labeled erlotinib: a micro-PET study on mice with lung tumor xenografts. Cancer Res., 2009, 69(3), 873-878.
39. Kawamura, K.; Yamasaki, T.; Yui, J.; Hatori, A.; Konno, F.; Kumata, K.; Irie, T.; Fukumura, T.; Suzuki, K.; Kanno, I.; Zhang, M. In vivo evaluation of P-glycoprotein and breast cancer resistance protein modulation in the brain using [(11)C]gefitinib. Nucl. Med. Biol., 2009, 36(3), 239-246.
40. Kurdziel, K.A.; Kalen, J.D.; Hirsch, J.I.; Wilson, J.D.; Agarwal, R.; Barrett, D.; Bear, H.D.; McCumiskey, J.F. Imaging multidrug resistance with 4-[18F]fluoropaclitaxel. Nucl. Med. Biol., 2007, 34(7), 823-831.
41. Fung, K.L.; Gottesman, M.M. A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function. Biochim. Biophys. Acta, 2009, 1794(5), 860-871.
42. Kimchi-Sarfaty, C.; Oh, J.M.; Kim, I.W.; Sauna, Z.E.; Calcagno, A.M.; Ambudkar, S.V.; Gottesman, M.M. A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science, 2007, 315(5811), 525-528.
43. Ambudkar, S.V.; Kimchi-Sarfaty, C.; Sauna, Z.E.; Gottesman, M.M. P-glycoprotein: from genomics to mechanism. Oncogene, 2003, 22(47), 7468-7485.
44. Li, J.; Cusatis, G.; Brahmer, J.; Sparreboom, A.; Robey, R.W.; Bates, S.E.; Hidalgo, M.; Baker, S.D. Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients. Cancer Biol. Ther., 2007, 6(3), 432-438.
45. Cusatis, G.; Gregorc, V.; Li, J.; Spreafico, A.; Ingersoll, R.G.; Verweij, J.; Ludovini, V.; Villa, E.; Hidalgo, M.; Sparreboom, A.; Baker, S.D. Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. J. Natl. Cancer Inst., 2006, 98(23), 1739-1742.
46. Sparreboom, A.; Loos, W.J.; Burger, H.; Sissung, T.M.; Verweij, J.; Figg, W.D.; Nooter, K.; Gelderblom, H. Effect of ABCG2 genotype on the oral bioavailability of topotecan. Cancer Biol. Ther., 2005, 4(6), 650-658.
47. Sparreboom, A.; Gelderblom, H.; Marsh, S.; Ahluwalia, R.; Obach, R.; Principe, P.; Twelves, C.; Verweij, J.; McLeod, H.L. Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype. Clin.Pharmacol. Ther., 2004, 76(1), 38-44.
48. Schinkel, A.H.; Smit, J.J.; van Tellingen, O.; Beijnen, J.H.; Wagenaar, E.; van Deemter, L.; Mol, C.A.; van der Valk, M.A.; Robanus-Maandag, E.C.; te Riele, H.P.; Berns, A.J.; Borst, P. Disruption of mouse mdr-1a p-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell, 1994, 77, 491-502.
49. Wijnholds, J.; deLange, E.C.; Scheffer, G.L.; van den Berg, D.J.; Mol, C.A.; van der Valk, M.; Schinkel, A.H.; Scheper, R.J.; Breimer, D.D.; Borst, P. Multidrug resistance protein 1 protects the choroid plexus epithelium and contributes to the bloodcerebrospinal fluid barrier. J.Clin. Invest., 2000, 105(3), 279-285.
50. Breedveld, P.; Pluim, D.; Cipriani, G.; Wielinga, P.; van Tellingen, O.; Schinkel, A.H.; Schellens, J.H. The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients. Cancer Res., 2005, 65(7), 2577-2582.
51. de Vries, N.A.; Zhao, J.; Kroon, E.; Buckle, T.; Beijnen, J.H.; van Tellingen, O. P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan. Clin. Cancer Res., 2007, 13(21), 6440-6449.
52. Polli, J.; Olson, K.; Chism, J.; John-Williams, L.; Yeager, R.; Woodard, S.; Otto, V.; Castellino, S.; Demby, V. An unexpected synergist role of P-glycoprotein and breast cancer resistance protein on the central nervous system penetration of the tyrosine kinase inhibitor lapatinib (N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; GW572016). Drug Metab. Dispos., 2009, 37(2), 439-442.
53. Lagas, J.S.; van Waterschoot, R.A.; van Tilburg, V.A.; Hillebrand, M.J.; Lankheet, N.; Rosing, H.; Beijnen, J.H.; Schinkel, A.H. Brain accumulation of dasatinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by elacridar treatment. Clin. Cancer Res., 2009, 15(7), 2344-2351.
54. Lagas, J.; van Waterschoot, R.; Sparidans, R.; Wagenaar, E.; Beijnen, J.; Schinkel, A. Breast cancer resistance protein and Pglycoprotein limit sorafenib brain accumulation. Mol. Cancer Ther., 2010, 9(2), 319-326.
55. Zhou, L.; Schmidt, K.; Nelson, F.R.; Zelesky, V.; Troutman, M.D.; Feng, B. The effect of breast cancer resistance protein and Pglycoprotein on the brain penetration of flavopiridol, imatinib mesylate (Gleevec), prazosin, and 2-methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propanoic acid (PF-407288) in mice. Drug Metab. Dispos., 2009, 37(5), 946-955.
56. Tang, S.C.; Lagas, J.S.; Lankheet, N.; Rosing, H.; Beijnen, J.H.; Schinkel, A.H. P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) limit sunitinib brain accumulation which can be enhanced by oral elacridar treatment. Proc. Am. Assoc. Cancer Res., 2010, 51.
57. Kodaira, H.; Kusuhara, H.; Ushiki, J.; Fuse, E.; Sugiyama, Y. Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone. J. Pharmacol. Exp. Ther., 2010, 333(3), 788-796.
58. de Bruin, M.; Miyake, K.; Litman, T.; Robey, R.; Bates, S.E. Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR. Cancer Lett., 1999, 146(2), 117-126.
59. Robey, R.W.; Steadman, K.; Polgar, O.; Morisaki, K.; Blayney, M.; Mistry, P.; Bates, S.E. Pheophorbide a is a specific probe for ABCG2 function and inhibition. Cancer Res., 2004, 64(4), 1242-1246.
60. Minderman, H.; O'Loughlin, K.L.; Pendyala, L.; Baer, M.R. VX-710 (biricodar) increases drug retention and enhances chemosensitivity in resistant cells overexpressing P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein. Clin. Cancer Res., 2004, 10(5), 1826-1834.
61. Bihorel, S.; Camenisch, G.; Lemaire, M.; Scherrmann, J.M. Modulation of the brain distribution of imatinib and its metabolites in mice by valspodar, zosuquidar and elacridar. Pharm. Res., 2007, 24(9), 1720-1728.
62. Loscher, W.; Potschka, H. Blood-brain barrier active efflux transporters: ATP-binding cassette gene family. NeuroRx, 2005, 2(1), 86-98.
63. Lazarowski, A.; Czornyj, L.; Lubienieki, F.; Girardi, E.; Vazquez, S.; D'Giano, C. ABC transporters during epilepsy and mechanisms underlying multidrug resistance in refractory epilepsy. Epilepsia, 2007, 48(Suppl. 5), 140-149.
64. Kannan, P.; John, C.; Zoghbi, S.; Halldin, C.; Gottesman, M.; Innis, R.; Hall, M. Imaging the function of P-glycoprotein with radiotracers: pharmacokinetics and in vivo applications. Clin. Pharmacol. Ther., 2009, 86(4), 368-377.
65. Kreisl, W.C.; Liow, J.S.; Kimura, N.; Seneca, N.; Zoghbi, S.S.; Morse, C.L.; Herscovitch, P.; Pike, V.W.; Innis, R.B. P-glycoprotein function at the blood-brain barrier in humans can be quantified with the substrate radiotracer 11C-N-desmethylloperamide. J. Nucl. Med., 2010, 51(4), 559-566.
66. Lhomme, C.; Joly, F.; Walker, J.L.; Lissoni, A.A.; Nicoletto, M.O.; Manikhas, G.M.; Baekelandt, M.M.; Gordon, A.N.; Fracasso, P.M.; Mietlowski, W.L.; Jones, G.J.; Dugan, M.H. Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer. J. Clin. Oncol., 2008, 26(16), 2674-2682.
67. Friedenberg, W.R.; Rue, M.; Blood, E.A.; Dalton, W.S.; Shustik, C.; Larson, R.A.; Sonneveld, P.; Greipp, P.R. Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Group. Cancer, 2006, 106(4), 830-838.
68. Baer, M.R.; George, S.L.; Dodge, R.K.; O'Loughlin, K.L.; Minderman, H.; Caligiuri, M.A.; Anastasi, J.; Powell, B.L.; Kolitz, J.E.; Schiffer, C.A.; Bloomfield, C.D.; Larson, R.A. Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood, 2002, 100(4), 1224-1232.
69. Greenberg, P.L.; Lee, S.J.; Advani, R.; Tallman, M.S.; Sikic, B.I.; Letendre, L.; Dugan, K.; Lum, B.; Chin, D.L.; Dewald, G.; Paietta, E.; Bennett, J.M.; Rowe, J.M. Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995). J. Clin. Oncol., 2004, 22(6), 1078-1086.
70. Saeki, T.; Nomizu, T.; Toi, M.; Ito, Y.; Noguchi, S.; Kobayashi, T.; Asaga, T.; Minami, H.; Yamamoto, N.; Aogi, K.; Ikeda, T.; Ohashi, Y.; Sato, W.; Tsuruo, T. Dofequidar fumarate (MS-209) in combination with cyclophosphamide, doxorubicin, and fluorouracil for patients with advanced or recurrent breast cancer. J. Clin. Oncol., 2007, 25(4), 411-417.